The abstract is read at the publisher; the summary is JClub's.
In orthotopic hepatocellular carcinoma models, GPC3-targeted paired PET imaging and alpha therapy achieved strong tumor uptake (>200 %IA/g) and excellent local control after a single 9.3 kBq dose.
- Why it matters: Liver cancer has unmet needs for tumor-selective diagnostics that can also predict and monitor response to targeted alpha particle therapy.
- What they did: Codrituzumab (GC33) was used to build [89Zr]Zr-DFO-GC33 for immunoPET and [225Ac]Ac-Macropa-GC33 for therapy, tested in orthotopic HepG2 and Hep3B luciferase models with biodistribution, QPID spectral autoradiography, and efficacy endpoints including BLI and overall survival.
- The result: Therapeutic [225Ac]Ac-Macropa-GC33 showed excellent local control with several complete pathologic responses and improved overall survival versus control, and longitudinal 89Zr-GC33 immunoPET correlated with BLI.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.